Home
>
US Stocks
>
Moleculin Biotech Inc
Moleculin Biotech Inc
MBRX

Moleculin Biotech Inc

$2.718.75%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
2.71
Today Low/High
2.71 / 2.71
52 Week Low/High
$2.72 / $43.92
Market Cap
$77.95M

Company Details

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a NextGeneration Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.
Organisation
Moleculin Biotech Inc
Headquaters
Houston, Texas, United States
Employees
13
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Moleculin Biotech Inc share price today

Can Indians buy Moleculin Biotech Inc shares?

How can I buy Moleculin Biotech Inc shares from India?

Can Fractional shares of Moleculin Biotech Inc be purchased?

What are the documents required to start investing in Moleculin Biotech Inc stocks?

We are a SEBI registered investement advisor